Johnson & Johnson
—- Market cap
- —
- Debt
- +$47.94B
- Cash
- −$19.71B
Complete market value, debt and cash evidence is required for enterprise value.
Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
Decision snapshot: JNJ stock price vs AMGN: inconclusive — current versus $296.46 implied using P/E multiple.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at AMGN's multiple
Implied fair value · at JNJ's multiple
Needs JNJ P/E.
Snapshot Sep 10, 2026, 4:00 PM ET
Metric by metric
Where each company leads, and how wide the gap is.
Growth lag
Reported gross margin
Operating income + D&A
Lower is better
Not comparable
Lower leverage
Statements
Annual statements in reported currencies, with calculations and source evidence.
Values retain reported currencies and share bases. Select a figure to inspect its period, calculation and filing inputs. Differences require compatible units and periods.
Explore enterprise value and market valuation multiples in the valuation sections.
Trendline
Nine period-end years of reported revenue, earnings, and margins. Periods and currencies are shown with the data.
Price framework
USD market cap plus reported borrowing debt, less cash and equivalents. This EV proxy excludes investments, preferred stock and noncontrolling-interest adjustments.
Complete market value, debt and cash evidence is required for enterprise value.
Capital structure 79% equity / 21% debt · EV / Revenue 6.86x · EV proxy / EBITDA proxy 17.71x
Price framework
The same filing-backed model used on each company's valuation page, with company-specific inputs and calculated scenarios.
Johnson & Johnson · implied price per share
Bear
$76.44
Base
$92.02
Bull
$112.30
Amgen Inc. · implied price per share
Bear
$121.60
Base
$161.79
Bull
$216.01
Balance sheet health
Inspect reported liquidity and leverage alongside historical financial-health checks.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Not enough data to score either balance sheet.
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
Cash excludes investments. EBITDA is an operating-income-plus-D&A proxy. Missing borrowing categories remain unavailable; select a value to inspect its inputs.
LLM-powered synthesis
An explanation of the financial evidence. Check its snapshot date against the figures above.
This explanation uses an earlier data snapshot or evidence version. Review its generation date and the current figures, or refresh after signing in.
If you believe JNJ should re-rate toward AMGN's earnings multiple (i.e., market values AMGN-like ROIC/growth), then buy JNJ because AMGN-implied P/E produces a $272.03 JNJ (≈13.3% upside) while JNJ offers stronger net margin and materially lower leverage, improving downside protection.
JNJ's implied P/E price ($272.03) implies a 13.3% upside from the current $240.10, reflecting AMGN's higher P/E (24.7x) versus JNJ (21.8x). The implied price sits slightly above JNJ's historical band high ($264.11), while the current price is inside the historical band ($216.09 - $264.11).
Supporting Metrics